Treatment of Severe Henoch-Schoenlein Purpura Nephritis in Children.
- Author:
Jae Il SHIN
1
;
Jae Seung LEE
Author Information
1. The Institute of Kidney Disease, Department of Pediatrics Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea. jsyonse@yumc.yonsei.ac.kr
- Publication Type:Review
- Keywords:
Henoch-Schoenlein purpura;
Severe Henoch-Schoenlein purpura nephritis;
Intensive therapy;
Children
- MeSH:
Anticoagulants;
Child;
Humans;
Methylprednisolone;
Nephritis;
Plasma Exchange;
Prognosis;
Purpura, Schoenlein-Henoch;
Renal Insufficiency;
Thrombolytic Therapy
- From:Journal of the Korean Society of Pediatric Nephrology
2010;14(1):10-21
- CountryRepublic of Korea
- Language:English
-
Abstract:
The overall prognosis of Henoch-Schoenlein purpura (HSP) is favorable, but severe nephritis has a high risk of progression to end stage renal failure. Recent studies emphasize the importance of early treatment in children with severe HSP nephritis, but the treatment of severe HSP nephritis still remains controversial due to the rarity of randomized controlled studies in this field. Nevertheless, several intensive therapies, such as intravenous high-dose methylprednisolone pulse, immunosuppressive/cytotoxic drugs, fibrinolytic therapy, anticoagulants, antiplatelet agent and plasma exchange, have been used in children with severe HSP nephritis. In this review, we focus on the treatment of severe HSP nephritis in children.
